Q-omics provides the consensus-scored THOC6 profile across patient tissues and cancer cell-line models. THOC6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THOC6 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, THOC6 protein abundance shows 28,214 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where THOC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THOC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THOC6 survival associations across molecular data types. THOC6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THOC6 RNA expression–survival associations across cancer types. High THOC6 expression shows unfavorable associations in KIRC, MESO, UCS, ACC, LIHC and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THOC6 RNA expression.
This table summarizes THOC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for THOC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THOC6 shows higher tumor expression in COAD, KIRC, KIRP, HNSC, BLCA and LIHC. The COAD box plot shows higher THOC6 RNA expression in tumor versus normal tissue (log2 FC = +1.212, t-test p < 0.001).
This table shows molecular features associated with THOC6 in patient tissues and cancer cell lines. In patient samples, THOC6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, THOC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
